Learn More >

Ministry Status: Routine Monitoring and Engagement

Patient Evidence Submissions

Drug Review Schedule

The Ontario Public Drug Program is currently accepting submissions of patient evidence on the following drug products which will undergo review by the Committee to Evaluate Drugs within the next 12 months.

Drug products on this list include new chemical entities, new combination products and existing drug products with a new indication recently approved by Health Canada. At this time, drug products that are line extensions (such as additional strengths and new dosage forms) and drug products that are undergoing reconsideration (second review, etc.) will not be considered for patient submissions. The Ministry will re-evaluate this once additional experience on the process is gained.

For drug products accepted for Rapid Review process, best efforts will be made to provide maximal time for patient submissions. However, in view of the intent of Rapid Review, the review of a drug product accepted for Rapid Review will not be held if only to include presentation of patient submissions.

Registered patient groups are invited to provide patient evidence on any of the drugs listed below.

All submissions must be received by 5:00pm of the deadline date.

Generic Name Brand Name Manufacturer Indication / Type of Review Deadline for Patient Submissions
Pembrolizumab Keytruda Merck Canada Inc. Melanoma (adjuvant treatment) (pCODR) June 19, 2019
Rituximab Rituxan/
Rituxan SC
Hoffmann-La Roche Limited (Cancer Care Ontario submission) Lymphoma, CD20+, relapsed/refractory aggressive histology (with salvage chemotherapy and intent to proceed to stem cell transplant) June 10, 2019
Bendamustine
hydrochloride
Treanda Teva Canada Limited
(Cancer Care Ontario submission)
Chronic lymphocytic leukemia (first-line [where fludarabine considered inappropriate], in combination with rituximab) May 27, 2019
Abemaciclib TBD Eli Lilly Canada Inc. Breast cancer, advanced or metastatic (pCODR) May 22, 2019
Brigatinib Alunbrig Takeda Canada Inc. Non-small cell
lung cancer (pCODR)
May 22, 2019
Buprenorphine Sublocade Indivior Canada Ltd. Opioid use disorder,
treatment (CDR)
May 22, 2019
Daratumumab Darzalex Janssen Inc. Multiple myeloma
(newly diagnosed)
(pCODR)
May 22, 2019
Lenalidomide Revlimid Celgene Inc. Multiple myeloma,
newly diagnosed,
stem cell transplant
not intended (in combination withbortezomib/
dexamethasone)
(pCODR)
May 22, 2019
Trastuzumab (biosimilar) Ogivri BGP Pharma ULC Early breast cancer / metastatic breast cancer / metastatic gastric cancer (pCODR) May 22, 2019
Pembrolizumab Keytruda Merck Canada Inc. Lung cancer, non-squamous, non-small cell, metastatic (in combination with chemotherapy) (pCODR) May 9, 2019

See also:

Image:Pdf icon.gif To view PDF format files, you need to have Adobe Acrobat® Reader installed on your computer.
You can download this free software from the Adobe Web site.

For More Information

Call ServiceOntario, Infoline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559.
In Toronto, TTY (416)327-4282
Hours of operation: Monday to Friday, 8:30am - 5:00pm

 
  • Connect With Us
Facebook Twitter YouTube RSS